A5010219232- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- Thyroid and Parathyroid Surgery
- Lymphoma Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Medical Imaging and Pathology Studies
- Sarcoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Meningioma and schwannoma management
- Parathyroid Disorders and Treatments
- Head and Neck Anomalies
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Pituitary Gland Disorders and Treatments
- Ovarian cancer diagnosis and treatment
- Cytomegalovirus and herpesvirus research
- Lung Cancer Diagnosis and Treatment
- S100 Proteins and Annexins
- Neuroblastoma Research and Treatments
- Bone health and treatments
Institute of Oncology Research
2014-2025
Istituto Imaging della Svizzera Italiana
2019-2025
Università della Svizzera italiana
2023-2025
Ente Ospedaliero Cantonale
2019-2025
Ente Ospedaliero Ospedali Galliera
2013-2021
Repubblica e Cantone Ticino
2021
University of Zurich
2021
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2021
University Hospital of Zurich
2021
Laboratory for Biomedical Neurosciences
2020
The purpose of this study was to assess the prognostic value early (18)F-FDG PET using standardized uptake (SUV) compared with visual analysis in patients diffuse large B-cell lymphoma (DLBCL).Ninety-two newly diagnosed DLBCL underwent prospectively before and after 2 cycles chemotherapy (at midtherapy). Maximum SUV (SUVmax) mean (SUVmean) normalized body weight surface area, as well tumor-to-normal ratios, were computed on most intense areas. SUVs, their changes over time for predicting...
Interim <sup>18</sup>F-FDG PET (after 1–4 cycles of chemotherapy) may be useful for tailoring a risk-adapted therapeutic strategy in lymphoma. The purpose this study was to investigate whether semiquantification standardized uptake values (SUVs) help improve the prognostic value PET, compared with visual analysis, after 4 chemotherapy. <b>Methods:</b> In previous report, we showed that 65.7% reduction maximal SUV (SUVmax) between baseline (PET0) and 2 chemotherapy (PET2) better predicted...
Purpose [ 18 F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with aggressive lymphoma, but less known about utility PET in follicular lymphoma (FL). In a prospective study, we evaluated prognostic value performed during treatment at end 121 FL treated first-line immunochemotherapy. Patients Methods previously untreated high–tumor burden were six cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)...
To evaluate the role of (18)F-flurodeoxiglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in predicting malignancy thyroid nodules with indeterminate cytology.We analysed 87 patients who have been scheduled to undergo surgery for nodule cytology. All underwent (18)F-FDG-PET/CT, multiparametric neck ultrasonography (MPUS), and (99m)Tc-methoxyisobutylisonitrile scintigraphy ((99m)Tc-MIBI-scan). Histopathology was standard reference. We compared sensitivity (SE),...
The aim of this pilot study was to assess post-treatment apparent diffusion coefficient (ADC) changes diffuse large B-cell lymphoma lesions on respiratory-gated whole-body diffusion-weighted imaging (DWI), with integrated (18)F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (PET/CT) as the reference standard.A total 15 patients underwent both DWI (b = 50, 400, 800 s/mm(2)) and PET/CT before initiation after 4 cycles chemotherapy. ADC residual masses (lymph node organ...
Here, we describe the case of a 74-year-old male patient with high-risk prostate carcinoma who underwent positron-emission tomography/computed tomography (PET/CT) [68Ga]Ga-prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) for staging. [68Ga]Ga-PSMA-11 PET/CT detected an extensive area increased tracer uptake at prostatic level, involving both lobes. Additionally, rounded lesion approximately 4 cm in diameter was identified celiac region adjacent to stomach, exhibiting moderate uptake....
The treatment landscape of prostate cancer is quite complex because the many therapeutic options available in different disease settings (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, radiopharmaceutical therapy). Since most cases we do not have comparative studies between these agents, best sequence patients with remains unsolved. In this review, describe systemic each setting from localized to metastatic castration-resistant disease. We also...
Abstract Objective Ultrasound (US) risk stratification systems (RSSs) have been developed to reduce the number of unnecessary fine‐needle aspiration (FNA) biopsies in patients with thyroid nodules. Autonomously functioning nodules (AFTN) account for 5%‐10% palpable lesions and are very rarely malignant. The present study was undertaken investigate how RSSs classify AFTNs whether able avoid FNA such cases. Methods Patients AFTN who had undergone US, scintigraphy function evaluation from...
Both cabazitaxel and lutetium-177 prostate-specific membrane antigen (Lu-PSMA) improve survival in metastatic castration-resistant prostate cancer (mCRPC) after an androgen receptor pathway inhibitor docetaxel, but there are limited data regarding Lu-PSMA activity cabazitaxel.
Background: [18F]-Fluorodeoxyglucose (FDG)-avid thyroid lesions incidentally detected on positron emission tomography/computed tomography (PET/CT) scans represent a tumor lesion in about 30% of cases. The present study evaluated the ability PET metrics and radiomics features to predict final diagnosis [18F]FDG incidentalomas (TIs). Methods: A total 104 patients with 107 TIs were retrospectively studied; 30 nodules (28%) diagnosed as malignant. After volumetric segmentation each lesion,...
As ~25% of cytologically indeterminate thyroid nodules harbour malignancy, diagnostic lobectomy is still performed in many cases. 18FDG PET/CT rules out malignancy visually negative nodules; however, none the currently available interpretation criteria differentiates malignant from benign 18FDG-avid nodules. We evaluated ability PET metrics and radiomics features (RFs) to predict final diagnosis nodules.Seventy-eight patients were retrospectively included. After volumetric segmentation each...
Here, we describe the case of a 43-year-old male patient with metastatic parathyroid carcinoma who underwent dual-tracer whole-body positron emission tomography/computed tomography (PET/CT) [18F]fluorocholine and fluorodeoxyglucose ([18F]FDG) for staging. [18F]FDG PET/CT detected multiple cervical mediastinal lymph nodal lesions increased tracer uptake, whereas uptake on bone lung better evaluation spread. Due to these imaging findings, systemic treatment chemotherapy. This demonstrates...
The present study was undertaken to evaluate the ablation rate after administration of 1.1 or 3.7 GBq iodine- (¹³¹I) patients with low-risk differentiated thyroid carcinoma (DTC) primarily treated by lobectomy.Enrolled were 136 consecutive affected histologically proven DTC previously lobectomy. Patients randomized receive a single dose ¹³¹I in an equivalence trial. Successful defined as negative diagnostic whole-body scan and stimulated thyroglobulin levels lower than 2 ng/ml absence...